All In Biotech

NDA 020062 · Bausch

Cardizem Cd

Diltiazem Hydrochloride · Oral

Last checked: Nov 19, 2026Latest source record: Apr 16, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1991

Dec 27, 1991

Approved uses

3

Original approval plus efficacy supplements

Registered trials

127

21 Phase 3, 6 recruiting

FAERS reports

14,723

12,051 serious, 3,123 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 10, 2025.

INDICATIONS AND USAGE CARDIZEM CD is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive medications. CARDIZEM CD is indicated for the management of chronic stable angina and angina due to coronary artery spasm.

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 15, 1992 Supplement 1 · Efficacy
  • Aug 10, 1992 Supplement 3 · Efficacy
  • Dec 27, 1991 Original approval · Type 5 - New Formulation or New Manufacturer
5 products under this application
  • CARDIZEM CD · DILTIAZEM HYDROCHLORIDE 300MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB3
  • CARDIZEM CD · DILTIAZEM HYDROCHLORIDE 180MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB3
  • CARDIZEM CD · DILTIAZEM HYDROCHLORIDE 360MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB3
  • CARDIZEM CD · DILTIAZEM HYDROCHLORIDE 240MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB3
  • CARDIZEM CD · DILTIAZEM HYDROCHLORIDE 120MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB3

Clinical trials

Interventional ClinicalTrials.gov studies with "Diltiazem" as an intervention, any sponsor and status, largest first.

All 127 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea1,626
  • pain1,418
  • fatigue1,372
  • fall1,184
  • nausea1,095
  • dizziness1,075
  • headache1,075
  • diarrhoea1,056
  • drug ineffective1,039
  • arthralgia1,021
  • hypotension952
  • pruritus931

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004500
2005507
2006366
2007256
2008263
2009261
2010346
2011334
2012459
2013426
2014504
2015445
2016572
2017521
2018473
2019502
2020675
2021990
20221,520
20231,163
20241,429
20251,387
2026824

Recalls

4 FDA enforcement reports for this application.

  • Jan 30, 2019 · Class III · Terminated

    Failed Dissolution Specifications: high out of specification results for dissolution when measuring the amount of drug released at certain time points.

  • Jan 30, 2019 · Class III · Terminated

    Failed Dissolution Specifications: high out of specification results for dissolution when measuring the amount of drug released at certain time points.

  • Jan 30, 2019 · Class III · Terminated

    Failed Dissolution Specifications: high out of specification results for dissolution when measuring the amount of drug released at certain time points.

  • Jan 30, 2019 · Class III · Terminated

    Failed Dissolution Specifications: high out of specification results for dissolution when measuring the amount of drug released at certain time points.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Cardizem CD (Diltiazem HCl)

2024 spending

$3.7M

Beneficiaries

451

1,422 claims

Per beneficiary

$8,305

$40.59 per unit

View as table
YearSpending
2020$3,928,724
2021$3,650,700
2022$3,482,843
2023$3,265,293
2024$3,745,623

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,211 on PubMed

Sponsor: Bausch

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.